Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Appointed COO
|
|
KERYX BIOPHARMACEUTICALS INC (KERX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 11/08/2018 |
8-K
| Quarterly results |
| 08/08/2018 |
8-K
| Quarterly results |
| 05/10/2018 |
8-K
| Quarterly results|
Docs:
|
"FORM 8-K",
"Notes Exchange Agreement, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C",
"Indenture, between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A",
"Registration Rights Agreement, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C",
"Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on May 10, 2018" |
|
| 02/07/2018 |
8-K
| Quarterly results |
| 11/07/2017 |
8-K
| Quarterly results |
| 07/27/2017 |
8-K
| Quarterly results |
| 05/04/2017 |
8-K
| Form 8-K - Current report |
| 03/01/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/01/2016 |
8-K
| Quarterly results |
| 04/28/2016 |
8-K
| Quarterly results |
| 11/04/2013 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results NEW YORK, October 30, 2013 /PRNewswire-FirstCall/ — Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease , today announced its results for the third quarter ended September 30, 2013. At September 30, 2013, the Company had cash, cash equivalents and interest receivable of $67.9 million, as compared to $14.7 million at December 31, 2012. In July 2013, the Company paid a $2.0 million New Drug Application user fee related to the submission of its NDA filing to the Food and Drug Administration . In October 2013, the Company received a full refund of the $2.0 million ND...",
"Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex™ Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus and Iron Deficiency Anemia" |
|
| 07/31/2013 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2013 Financial Results Keryx to Host Investor Conference Call on Thursday, August 1, 2013 at 8:30am EDT NEW YORK, July 31, 2013 /PRNewswire-FirstCall/ — Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease , today announced its results for the second quarter ended June 30, 2013. At June 30, 2013, the Company had cash, cash equivalents, interest receivable, and investment securities of $80.4 million, as compared to $14.7 million at December 31, 2012. On January 30, 2013, the Company completed an underwritten public offering of common stock, which provided proceeds to the Company of appr..." |
|
| 11/07/2012 |
8-K
| Quarterly results|
Docs:
|
"Selected Consolidated Financial Data Statements of Operations Information : Three Months Ended September 30, Nine Months Ended September 30, 2012 2011 2012 2011 REVENUE: License revenue $ -- $ -- $ -- $ 5,000 OPERATING EXPENSES: Research and development: Non-cash compensation 161 152 512 616 Other research and development 3,768 8,620 14,616 19,533 Total research and development 3,929 8,772 15,128 20,149 General and administrative: Non-cash compensation 384 320 1,117 948 Other general and administrative 1,213 1,263 4,156 3,951 Total general and administrative 1,597 1,583 5,273 4,899 TOTAL OPERATING EXPENSES 5,526 10,355 20,401 25,048 OPERATING LOSS OTHER INCOME: Interest and other income, net 51 108 1,669 300 LOSS BEFORE EXTRAORDINARY GAIN EXTRAORDINARY GAIN -- -- 2,639 -- NET LOSS $ $ ...",
"Keryx Biopharmaceuticals Initiates Phase 2 Study of Zerenex TM for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease" |
|
| 08/07/2012 |
8-K
| Quarterly results |
| 05/08/2012 |
8-K
| Form 8-K - Current report |
| 02/29/2012 |
8-K
| Quarterly results|
Docs:
|
"Selected Consolidated Financial Data Statements of Operations Information : Three Months Ended December 31, Year Ended December 31, 2011 2010 2011 2010 REVENUE: License revenue $ -- $ -- $ 5,000 $ -- OPERATING EXPENSES: Research and development: Non-cash compensation 187 238 803 1,236 Other research and development 6,676 4,144 26,209 13,728 Total research and development 6,863 4,382 27,012 14,964 General and administrative: Non-cash compensation 341 278 1,289 1,237 Other general and administrative 1,497 1,341 5,448 5,014 Total general and administrative 1,838 1,619 6,737 6,251 TOTAL OPERATING EXPENSES 8,701 6,001 33,749 21,215 OPERATING LOSS OTHER INCOME: Interest and other income, net 80 567 380 764 LOSS FROM CONTINUING OPERATIONS Gain from discontinued operations 246 120 246 120 NET ..." |
|
| 11/02/2011 |
8-K
| Form 8-K - Current report |
| 08/08/2011 |
8-K
| Form 8-K - Current report |
| 05/02/2011 |
8-K
| Form 8-K - Current report |
| 03/08/2011 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results Keryx to Host Investor Conference Call on Wednesday, March 9, 2011 at 8:30am EST NEW YORK, March 8, 2011 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease , today announced its results for the fourth quarter and year ended December 31, 2010. At December 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $28.5 million, as compared to $35.9 million at December 31, 2009. The net loss for the fourth quarter ended December 31, 2010 was $5.3 million, or $0.09 per share..." |
|
| 08/09/2010 |
8-K
| Form 8-K - Current report |
| 05/10/2010 |
8-K
| Quarterly results|
Docs:
|
"Keryx to Host Investor Conference Call on Tuesday, May 11, 2010 at 8:30am EDT NEW YORK, May 10, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease , today announced its results for the first quarter ended March 31, 2010. At March 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $32.1 million, as compared to $35.9 million at December 31, 2009. Subsequent to March 31, 2010, the Com pany has received approximately $2.7 million of cash proceeds from the exercise of options and warrants. The net loss for the first q..." |
|
| 03/24/2010 |
8-K
| Form 8-K - Current report |
| 11/09/2009 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results Keryx to Host Investor Conference Call on Tuesday, November 10, 2009 at 8:30am EST NEW YORK, November 9, 2009 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease , today announced its results for the third quarter ended September 30, 2009. At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direc..." |
|
| 08/05/2009 |
8-K
| Form 8-K - Current report |
| 05/13/2009 |
8-K
| Form 8-K -- Current report |
| 03/12/2009 |
8-K
| Quarterly results |
| 11/10/2008 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results Keryx to Host Investor Conference Call on Tuesday, November 11, 2008 at 8:30am EST NEW YORK, November 10, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the third quarter ended September 30, 2008. At September 30, 2008, the Company had cash, cash equivalents, investment securities and interest receivable of $26.5 million, as compared to $64.7 million at December 31, 2007. Approximately $9.2 million of the Company’s investments, at September ...",
"Keryx Biopharmaceuticals’ KRX-0401 Data Selected for Oral Presentation at the 50 th Annual Meeting of the American Society of Hematology",
"Abstract of Study Entitled “Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib.”" |
|
| 08/08/2008 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results Keryx to Host Investor Conference Call on Monday, August 11, 2008 at 8:30am EDT NEW YORK, August 8, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the second quarter ended June 30, 2008. At June 30, 2008, the Company had cash, cash equivalents, investment securities and interest receivable of $34.6 million, as compared to $64.7 million at December 31, 2007. Approximately $10.1 million of the Company’s investments, at June 30, 2008, represen..." |
|
| 05/12/2008 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results Keryx to Host Investor Conference Call on Monday, May 12, 2008 at 8:30am EDT NEW YORK, May 9, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer, today announced its results for the first quarter ended March 31, 2008. At March 31, 2008, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $47.6 million, as compared to $64.7 million at December 31, 2007. In April 2008, we received a payment of $8.0 million that was classifi..." |
|
| 02/22/2008 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results Keryx to Host Investor Conference Call on Monday, February 25, 2008 at 8:30am EST NEW YORK, February 22, 2008 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer , today announced its results for the fourth quarter and year ended December 31, 2007. At December 31, 2007, the Company had cash, cash equivalents, investment securities and interest receivable of $64.7 million, as compared to $125.6 million at December 31, 2006. The net loss for the fourth quarter ended December 3..." |
|
| 10/24/2007 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results Keryx to Host Investor Conference Call on Thursday, October 25, 2007 at 8:30am EDT NEW YORK, October 24, 2007 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, today announced its results for the third quarter ended September 30, 2007. At September 30, 2007, the Company had cash, cash equivalents, investment securities, interest receivable and license receivable of $82.7 million, as compared to $125.6 million at December 31, 2006. The nonrefundable license receivable of $12.0 million w..." |
|
| 07/25/2007 |
8-K
| Quarterly results|
Docs:
|
"Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results Keryx to Host Investor Conference Call on Thursday, July 26, 2007 at 8:30am EDT NEW YORK, July 25, 2007 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer, today announced its results for the second quarter ended June 30, 2007. At June 30, 2007, the Company had cash, cash equivalents, investment securities and interest receivable of $88.3 million, as compared to $125.6 million at December 31, 2006. The net loss for the second quarter ended June 30, 2007 was $19,460,000, or $0.45 per sha..." |
|
|
|
|